Title:
BISPECIFIC ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/002036
Kind Code:
A1
Abstract:
Provided are a bispecific antibody and a use thereof. The bispecific antibody comprises an antigen binding domain targeting B7-H4 and an antigen binding domain targeting 4-1BB. The bispecific antibody has one, two, or three binding sites for 4-1BB, and at the same time has a brand new fully human B7-H4 antibody. The bispecific antibody specifically binds to tumor cells by targeting B7-H4, thus reducing the toxicity caused by the activation of 4-1BB. In addition, the bispecific antibody has a human Fc fragment, retains the binding effect of Fc and FcRn, and has a relatively long half-life.
Inventors:
SHI LEI (CN)
ZHONG CHEN (CN)
WU XIAODONG (CN)
HE YUN (CN)
CHEN FEI (CN)
LV XIAOCHENG (CN)
XIE JINLI (CN)
RONG YIPING (CN)
HUANG BING (CN)
DU FANGFANG (CN)
ZHAO JIANXUN (CN)
ZHONG CHEN (CN)
WU XIAODONG (CN)
HE YUN (CN)
CHEN FEI (CN)
LV XIAOCHENG (CN)
XIE JINLI (CN)
RONG YIPING (CN)
HUANG BING (CN)
DU FANGFANG (CN)
ZHAO JIANXUN (CN)
Application Number:
PCT/CN2021/103058
Publication Date:
January 06, 2022
Filing Date:
June 29, 2021
Export Citation:
Assignee:
HARBOUR BIOMED SHANGHAI CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C07K16/46
Domestic Patent References:
| WO2017147368A1 | 2017-08-31 | |||
| WO2020107715A1 | 2020-06-04 | |||
| WO2018195302A1 | 2018-10-25 | |||
| WO2016040724A1 | 2016-03-17 | |||
| WO2010109165A2 | 2010-09-30 | |||
| WO2009080251A1 | 2009-07-02 | |||
| WO2009080252A1 | 2009-07-02 |
Foreign References:
| CN109476747A | 2019-03-15 | |||
| CN109563503A | 2019-04-02 | |||
| CN101951959A | 2011-01-19 | |||
| CN202010618149A | 2020-06-30 |
Other References:
IIZUKA AKIRA, ET AL.: "A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 25, no. 9, 1 May 2019 (2019-05-01), US, pages 2925 - 2934, XP055811280, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-3123
SMITH JENESSA B.; STASHWICK CAITLIN; POWELL DANIEL J.: "B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, vol. 134, no. 1, 1 January 1900 (1900-01-01), GB , pages 181 - 189, XP028874738, ISSN: 0090-8258, DOI: 10.1016/j.ygyno.2014.03.553
LIU YAN, FU KAIFEI, ZHOU LIJUN: "Advances in Bispecific Antibodies for Tumor Treatment", THE JOURNAL OF PRACTICAL MEDICINE, SHI YONG YI XUE ZA ZHI SHE, CN, vol. 33, no. 18, 31 December 2017 (2017-12-31), CN , pages 3141 - 3144, XP055884332, ISSN: 1006-5725, DOI: 10.3969/j.issn.1006-5725.2017.17.042
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH (U.S.
LAZIKANI ET AL., J MOL BIOL, vol. 273, 1997, pages 927 - 948
SCHLOTHAUER THERTER SKOLLER CFGRAU-RICHARDS SSTEINHART VSPICK CKUBBIES MKLEIN CUMANA PMOSSNER E: "Novel human IgG 1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions", PROTEIN ENGDES SEL, vol. 29, no. 10, 29 August 2016 (2016-08-29), pages 457 - 466, XP055414310, DOI: 10.1093/protein/gzw040
SMITH JENESSA B.; STASHWICK CAITLIN; POWELL DANIEL J.: "B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, vol. 134, no. 1, 1 January 1900 (1900-01-01), GB , pages 181 - 189, XP028874738, ISSN: 0090-8258, DOI: 10.1016/j.ygyno.2014.03.553
LIU YAN, FU KAIFEI, ZHOU LIJUN: "Advances in Bispecific Antibodies for Tumor Treatment", THE JOURNAL OF PRACTICAL MEDICINE, SHI YONG YI XUE ZA ZHI SHE, CN, vol. 33, no. 18, 31 December 2017 (2017-12-31), CN , pages 3141 - 3144, XP055884332, ISSN: 1006-5725, DOI: 10.3969/j.issn.1006-5725.2017.17.042
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH (U.S.
LAZIKANI ET AL., J MOL BIOL, vol. 273, 1997, pages 927 - 948
SCHLOTHAUER THERTER SKOLLER CFGRAU-RICHARDS SSTEINHART VSPICK CKUBBIES MKLEIN CUMANA PMOSSNER E: "Novel human IgG 1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions", PROTEIN ENGDES SEL, vol. 29, no. 10, 29 August 2016 (2016-08-29), pages 457 - 466, XP055414310, DOI: 10.1093/protein/gzw040
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: